AG2R LA Mondiale Gestion D Actifs Purchases 809 Shares of Merck & Co., Inc. $MRK

AG2R LA Mondiale Gestion D Actifs increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 0.9% in the second quarter, HoldingsChannel reports. The firm owned 94,279 shares of the company’s stock after buying an additional 809 shares during the period. AG2R LA Mondiale Gestion D Actifs’ holdings in Merck & Co., Inc. were worth $7,463,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Little House Capital LLC raised its position in shares of Merck & Co., Inc. by 1.2% in the second quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock valued at $1,998,000 after purchasing an additional 308 shares during the period. Semus Wealth Partners LLC grew its position in shares of Merck & Co., Inc. by 8.2% in the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock valued at $452,000 after purchasing an additional 382 shares during the last quarter. Longfellow Investment Management Co. LLC lifted its holdings in Merck & Co., Inc. by 20.4% during the 1st quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after purchasing an additional 3,282 shares during the last quarter. Quilter Plc lifted its holdings in Merck & Co., Inc. by 5.6% during the 1st quarter. Quilter Plc now owns 1,180,797 shares of the company’s stock worth $105,988,000 after purchasing an additional 62,933 shares during the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in Merck & Co., Inc. by 9.8% in the 2nd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock valued at $70,327,000 after purchasing an additional 79,529 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $87.54 on Friday. The firm has a 50 day moving average of $84.43 and a 200-day moving average of $81.54. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $106.49. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $218.65 billion, a PE ratio of 13.49, a PEG ratio of 0.96 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The business had revenue of $15.81 billion for the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on MRK. Citigroup began coverage on Merck & Co., Inc. in a report on Monday, October 13th. They set a “neutral” rating and a $95.00 target price for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Wells Fargo & Company decreased their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Morgan Stanley lowered their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Finally, Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price target for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $104.33.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.